MedTrace Logo

Investigation Into the Pathophysiology and Treatment of Varicose Veins

NCT06192472 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-01-05

No results posted yet for this study

Summary

Chemical sclerotherapy is commonly used to treat varicose veins which affect superficial veins in the leg. Sclerotherapy is injected directly into veins where it causes damage to the vein wall. If sufficient damage occurs, the vein is transformed into a fibrous cord which does not re-open. This study will investigate the structural changes caused to the wall of veins following injection with sclerotherapy ex vivo. Vein samples will be obtained from the Whiteley Clinic in Guildford from patients undergoing phlebectomy operations. These will then be injected with sclerotherapy and the extent of damage will be investigated. Samples will also be used for laboratory analysis into the pathophysiology of varicose veins.

Conditions

  • Varicose Veins

Interventions

DRUG

3% Sodium Tetradecyl Sulphate

3% Sodium Tetradecyl Sulphate

DRUG

0.5% Polidocanol

0.5% Polidocanol

PROCEDURE

Chemical sclerotherapy

Sclerosant will be retained within the vein

DRUG

1% Sodium Tetradecyl Sulphate

1% Sodium Tetradecyl Sulphate

DRUG

3% Polidcanol

3% Polidcanol

Sponsors & Collaborators

  • The Whiteley Clinic

    collaborator OTHER

  • University of Surrey

    lead OTHER

Principal Investigators

  • Christopher T Lee, MPharm · Univesity of Surrey

  • Jian-Mei Li, MBBS MD PhD · University of Surrey

  • Mark S Whiteley, MS · The Whiteley Clinic and University of Surrey

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2015-07-31
Completion
2015-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06192472 on ClinicalTrials.gov